Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2014008285
pages 49-88

Current Nanotechnological Strategies for Effective Delivery of Bioactive Drug Molecules in the Treatment of Tuberculosis

Mandeep Kaur
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab
Tarun Garg
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
Goutam Rath
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India; Punjab Technical University, Kapurthala, Punjab, India
Amit Kumar Goyal
Department of Pharmaceutics, ISF College of Pharmacy, Moga (Punjab), India; Punjab Technical University, Kapurthala, Punjab, India

SINOPSIS

Tuberculosis (TB) has gone from being a forgotten disease to a modern and recrudescent pathology from past decades. Some clinical problems and challenges associated with conventional TB chemotherapy include poor patient compliance, longer duration of chemotherapy, lesser cell permeability, primary drug resistance, difficulty in maintaining higher drug concentrations at the infected site, and degradation of the drug before reaching the target site. Thus, newer drug delivery approaches involving micrometric or nanometric carriers are needed. These delivery systems should provide advantages over conventional systems by producing optimum effectiveness to the target site, enhanced therapeutic efficacy, uniform distribution of the drug throughout the target site, increased bioavailability and sustainability of the drug, fewer side effects, and increased patient compliance. This article reviews recent updates and fabrication of drug delivery approaches for tuberculosis chemotherapy involving vesicular drug delivery systems (liposomes, niosomes, solid lipid nanoparticles), particulate drug delivery systems (nanoparticles, microparticles, dendrimers), supramolecular drug delivery systems (polymeric micelles), specialized drug delivery systems (nanosuspensions, nanoemulsions, microemulsions, dry powders), complex conjugate drug delivery systems (ISCOMs, cyclodextrin inclusion complexes), and other carrier-based drug delivery systems in order to improve patient outcomes.